EU regulators say AstraZeneca's jab should come with warning

EU medical regulators say AstraZeneca’s jab should come with clear warning that blood clots are a ‘very rare side effect’

  • European Medicines Agency says AstraZeneca jabs should come with a warning 
  • Most of the blood clots reported have occurred in women under 60 after a jab 
  • No specific risk factors for the clots have been identified on current evidence 

WHAT ARE THE SYMPTOMS OF THE RARE BLOOD CLOTS LINKED TO ASTRAZENECA’S VACCINE? 

  • Shortness of breath
  • Chest pain
  • Swelling of leg
  • Persistent stomach pain
  • Severe headache
  • Blurred vision
  • Skin bruising beyond the site of injection

The EU’s medical regulators have said that AstraZeneca’s vaccine should come with a clear warning that blood clots are a ‘very rare side effect’. 

The European Medicines Agency (EMA) said most of the cases of blood clots reported have occurred in women under 60 within two weeks of vaccination with the company’s jab.

No specific risk factors had been identified based on current evidence, the regulator confirmed at a press briefing this afternoon.

But the agency refused to back Germany and other nations banning the jabs for under-60s, saying they could not prove that age or gender was a risk factor for the ‘very rare’ side effect.

Health chiefs said they had spotted 169 cases of CVST and 53 cases of a separate blood clot called splanchnic vein thrombosis out of 34million doses dished out by April 4 – the equivalent of one blood clot for every 150,000 doses. But many of these clots would have occurred naturally, meaning the true risk will be smaller.

It comes as UK health chiefs ruled Britons under 30 should not take the company’s vaccine.

In a major blow to the UK’s vaccination rollout, the Government’s vaccine advisory group is recommending healthy people aged 19 to 29 be offered either the Pfizer or Moderna jabs instead when the programme moves to younger groups in the coming months.

Following a review of all available evidence, EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) said the blood clots reported had been found in veins in the brain, the abdomen and arteries, combined with low levels of blood platelets and sometimes bleeding.

The EMA said symptoms associated with the blood clots include shortness of breath, chest pain, swelling in the leg, persistent abdominal pain, severe headaches, blurred vision and tiny blood spots under the skin where the injection was administered.

Anyone who displayed them should seek medical attention, the EMA said.

The EU’s medical regulators have said that Astra Zeneca’s vaccine should come with a clear warning that blood clots are a ‘very rare side effect’. Pictured: European Medicines Agency executive director Emer Cooke

The committee carried out an in-depth review of 62 cases of clots in the brain and 24 cases of clots in the abdomen as of March 22, with 18 of the combines cases proving fatal.

They came from reporting systems in the European Economic Area and the UK, from around 25 million people who had received the vaccine.

Emer Cooke, executive director of the European Medicines Agency, said its review ‘confirmed that the benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects’.

She said: ‘Vaccination is extremely important in helping us in the fight against Covid-19.

‘This vaccine has proven to be highly effective. It is saving lives, vaccination is extremely important in helping us in the fight against Covid and we need to use the vaccine we have to protect us from the devastating effects.

‘We will continue to monitor the scientific evidence and issue further recommendations, if necessary, on the grounds of science and robust evidence.

‘When millions of people receive these vaccines, very rare events can occur that were not identified in clinical trials.

‘Our conclusion is that these clotting disorders are very rare side effects of the vaccine.’

The head of PRAC said the benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects.

Speaking at the briefing, Sabine Straus said: ‘This vaccine has proven to be highly effective, it prevents severe disease and hospitalisation and it is saving lives.

‘Vaccination is extremely important in helping us in the fight against Covid-19 and we need to use the vaccines we have to protect us from the devastating effects.

The EMA presented its review at a press briefing this afternoon, chaired by Emer Cooke (right), its executive director, Sabine Straus (centre), chair of PRAC, Peter Arlett, Head of Data Analytics and Methods Task Force

‘Prac, after a very in-depth analysis, has concluded that the reported cases of unusual blood clotting following vaccination of the AstraZeneca vaccine should be listed as possible side effects of the vaccine.’

Some 34million AstraZeneca jabs had been dished out in the EU by April 4, with 169 cases of CVS and 53 cases of splanchnic vein thrombosis. This is the equivalent of one in every 150,000 doses, according to Google.

The EMA said the updated figures – which were slightly higher than the headline numbers in the main release – did not change the recommendations.

Scientists believe the combination of clots and low blood platelets could be caused by an immune response leading to a condition similar to those seen in heparin patients.

Patients who use the blood thinner sometimes fall into heparin induced thrombocytopenia — a condition involving thrombosis. 

Leaked delivery schedules reveal the Government is expecting AstraZeneca’s vaccine to make up 75 per cent of its Covid jab supplies over the next two months. The document, published on the Scottish Government’s website in January and quickly taken down, showed Britain was anticipating about 29.4m doses of AstraZeneca’s jab between April and the first week of June. By comparison, officials expected just 8.5m of Pfizer’s vaccine in the next two months and 1m of the new Moderna jab, which is being rolled out for the first time in Wales today

It comes as a review by the UK drugs watchdog found that 79 out of 20million Britons vaccinated with the AstraZeneca vaccine had suffered deadly blood clots in the brain or arteries by the end of March. 

The cases came at a rate of about one in 250,000. Nineteen of the cases died and three were under the age of 30. 

Officials insisted there was still no concrete proof that the British-made vaccine is causing the clots, but admitted the link was getting firmer. 

They reiterated that halting its use in under-30s was precautionary until they can sure-up the link between the vaccine and the clots.

Britons over that age are still being advised to get the vaccine because the risk of Covid far outweighs the chance of developing the extremely conditions. 

But regulators said the balance of benefits and risks was ‘more finely balanced’ in younger people. 

A review by the European Medicines Agency’s safety committee concluded today that ‘unusual blood clots with low blood platelets should be listed as very rare side effects’ of the Oxford/AstraZeneca vaccine.

Prime Minister Boris Johnson said he will carefully follow the advice on the Oxford/AstraZeneca vaccine from the MHRA and JCVI but does not believe he will have to alter the schedule for easing the lockdown.

During a visit to Cornwall, he told broadcasters: ‘I think the crucial thing on this is to listen to what the scientists, and the doctors, the medical experts, have to say.

‘The MHRA is meeting, the JCVI is meeting, they’ll be setting out the position and we will get on with rolling out the vaccine and obviously we’ll follow very carefully what they have to say.

‘I don’t think anything that I have seen leads me to suppose that we will have to change the road map or deviate from the road map in any way.’

Source: Read Full Article